A PYMNTS Company

GlaxoSmithKline to pay $2.6 million for inflating Idaho Medicaid drug prices

By  |  April 17, 2012

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    GlaxoSmithKline has agreed to pay the state of Idaho $2.6 million to settle claims that it overcharged Idaho Medicaid. Idaho Attorney General Lawrence Wasden believes that the manufacturer inflated the average wholesale price of its drugs; for example, the price of Wellbutrin was found to be inflated by as much as 27 percent. Of the $2.6 million settlement, $1.544 million will go into the Cooperative Welfare Fund to reimburse the federal government. The remainder will go to the state: more than $620,000 will be deposited into the state’s general fund, and $50,000 will go into the consumer protection account for the Attorney General’s investigative and legal costs.

    Full content: Idaho Statesman

     

    Related content: Reversing the Trend? The Possibility that Rule Changes May Lead to Fewer Reverse Payments in Pharma Settlements (Anne Layne-Farrar, Compass Lexecon)

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.